<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Plasma cell leukemia</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Plasma cell leukemia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Plasma cell leukemia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">María-Victoria Mateos, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">S Vincent Rajkumar, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rebecca F Connor, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Plasma cell leukemia (PCL) is a rare, yet aggressive form of multiple myeloma (MM) characterized by plasma cells circulating in the peripheral blood that can be detected on conventional peripheral blood smear examination. PCL can either originate de novo (primary PCL) or as a secondary leukemic transformation of MM (secondary PCL).</p><p>The epidemiology, clinical presentation, diagnosis, prognosis, and treatment of plasma cell leukemia are discussed here. The related disorders of MM and plasmacytoma are presented separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6659.html" rel="external">"Solitary extramedullary plasmacytoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6653.html" rel="external">"Solitary plasmacytoma of bone"</a>.)</p><p></p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>PCL is a rare plasma cell disorder characterized by circulating plasma cells on conventional peripheral blood smear in patients otherwise meeting the criteria for multiple myeloma (MM)  (<a class="graphic graphic_table graphicRef57627" href="/z/d/graphic/57627.html" rel="external">table 1</a>). (See <a class="local">'Diagnostic criteria'</a> below.)</p><p>PCL is subclassified based on clinical presentation: </p><p class="bulletIndent1"><span class="glyph">●</span>Primary PCL – PCL as the initial manifestation of MM</p><p class="bulletIndent1"><span class="glyph">●</span>Secondary PCL – PCL as a leukemic transformation of previously diagnosed MM </p><p></p><p>Historically, most cases have been primary PCL (60 to 70 percent), although the distribution of disease is now more evenly split, perhaps due to an increased incidence of secondary PCL reflecting improved survival of patients with MM with treatment advances [<a href="#rid1">1,2</a>]. An estimated 1 to 4 percent of patients with MM progress to secondary PCL [<a href="#rid1">1,3,4</a>]. When compared with secondary PCL, primary PCL presents at a slightly younger age (median age 55 versus 66 years).  </p><p>PCL occurs in all geographic locations and in patients of all backgrounds. The reported incidence of PCL in the United States and Europe is approximately 4 cases per 10,000,000 persons per year [<a href="#rid5">5,6</a>]. The true incidence is likely higher as these data were collected before a change in the diagnostic criteria that decreased the required plasma cell percentage. As with MM, PCL is more common in Black Americans than in White populations [<a href="#rid5">5</a>].</p><p>The most extensive data on the epidemiology of PCL come from a series of 291 patients identified in the Surveillance, Epidemiology and End Results (SEER) database between 1973 and 2004 [<a href="#rid5">5</a>]. During this period, approximately 49,000 patients with MM were identified, for a relative incidence of 0.6 percent. In this series there were no significant differences based on sex, age, or race when compared with patients with MM. This SEER study did not distinguish between primary and secondary PCL. </p><p class="headingAnchor" id="H3"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Presenting signs and symptoms can include those seen in multiple myeloma (MM; eg, kidney dysfunction, hypercalcemia, lytic bone lesions, bone pain, anemia) and in other leukemias (eg, leukocytosis, anemia, thrombocytopenia, infections, hepatomegaly, splenomegaly). Approximately 40 to 50 percent of patients will have already been diagnosed with MM [<a href="#rid7">7</a>].</p><p>As an example, a retrospective analysis reported the following clinical features in patients presenting with PCL [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Median white blood cell count – 18.6 cells/microL</p><p class="bulletIndent1"><span class="glyph">●</span>Median hemoglobin – 9.2 g/dL</p><p class="bulletIndent1"><span class="glyph">●</span>Median platelet count – 75 platelets/microL</p><p class="bulletIndent1"><span class="glyph">●</span>Osteolytic lesions – 44 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Extramedullary plasmacytoma – 14 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatomegaly – 21 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Splenomegaly – 13 percent</p><p></p><p>Other findings that may be present on physical examination include lymphadenopathy, pulmonary findings related to pleural effusions, and neurologic deficits due to central nervous system involvement [<a href="#rid2">2</a>]. In addition, laboratory evaluation frequently demonstrates elevated levels of lactate dehydrogenase (LDH) and beta-2 microglobulin.</p><p class="headingAnchor" id="H4"><span class="h1">PATHOLOGIC FEATURES</span></p><p class="headingAnchor" id="H5"><span class="h2">Peripheral blood</span></p><p class="headingAnchor" id="H5211660"><span class="h3">Morphology</span><span class="headingEndMark"> — </span>The peripheral blood smear of patients with PCL demonstrates circulating plasma cells. To meet criteria for PCL, the proportion of plasma cells detected on conventional peripheral smear of the blood (manual white blood cell differential count) should be ≥5 percent [<a href="#rid8">8</a>]. (See <a class="local">'Diagnostic criteria'</a> below.)</p><p>The morphologic features of plasma cells can differ depending on their maturity and, at times, may be indistinguishable from myeloblasts. </p><p class="bulletIndent1"><span class="glyph">●</span>Mature plasma cells – Mature plasma cells are oval with abundant basophilic cytoplasm  (<a class="graphic graphic_picture graphicRef63684" href="/z/d/graphic/63684.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef76557" href="/z/d/graphic/76557.html" rel="external">picture 2</a>). The nucleus is round and eccentrically located with a marked perinuclear hof, or cytoplasmic clearing. The nucleus contains "clock-face" or "spoke wheel" chromatin without nucleoli. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immature plasma cells – Immature plasma cells have dispersed nuclear chromatin, prominent nucleoli and a high nuclear to cytoplasmic ratio.</p><p></p><p>Pathologic features of multiple myeloma (MM) are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Peripheral smear'</a> and  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Bone marrow'</a>.)</p><p class="headingAnchor" id="H5211666"><span class="h3">Immunophenotype</span><span class="headingEndMark"> — </span>The cytoplasm of the neoplastic plasma cells contains either kappa or lambda light chains, but not both, indicating that the cells are clonal. </p><p>The immunophenotype of PCL differs from that of MM. While both PCL and MM express the two common plasma cell markers CD38 and CD138, PCL demonstrates a more immature phenotype as reflected in [<a href="#rid9">9-11</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>More frequent expression of CD20, CD23, CD28, CD44, and CD45</p><p class="bulletIndent1"><span class="glyph">●</span>Less frequent expression of CD9, CD56, CD71, CD117, and HLA-DR antigens </p><p></p><p class="headingAnchor" id="H5211672"><span class="h3">Genetic features</span><span class="headingEndMark"> — </span>There is no single cytogenetic abnormality that is typical or diagnostic of PCL. Most cases will have complex cytogenetic abnormalities with a high frequency of abnormalities known to be associated with rapidly progressive, or high risk, MM. </p><p>Hypodiploid or diploid cells are present in more than 80 percent of cases [<a href="#rid2">2</a>]. The most common abnormalities are deletion of chromosome 13q and monosomy 13. Deletion 17p, resulting in loss of <em>TP53</em>, has been detected in almost half of primary PCL and three-quarters of secondary PCL. In addition, PCL frequently has abnormalities in chromosome 1, in particular 1q21 amplification and del(1p21). </p><p>In one retrospective study, patients with PCL were noted to have the following high-risk abnormalities [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>del13 – 67 to 85 percent</p><p class="bulletIndent1"><span class="glyph">●</span>t(4;14) – 16 percent</p><p class="bulletIndent1"><span class="glyph">●</span>t(14;16) – 16 percent</p><p class="bulletIndent1"><span class="glyph">●</span>del17p13 – 50 to 75 percent</p><p></p><p>This and other studies suggest that, when compared with MM, PCL has a higher incidence of t(11;14), t(14;16), and monosomy 13, with a similar incidence of t(4;14). </p><p>MYC rearrangements have also been found in PCL, although the reported incidence varies between 13 and 40 percent [<a href="#rid1">1,12,13</a>]. Other chromosomal abnormalities that have been identified in primary PCL include the loss of chromosomes 16 (80 percent) [<a href="#rid14">14</a>], 7 (11 percent) [<a href="#rid14">14</a>], and X (25 percent) [<a href="#rid15">15</a>], and trisomy of chromosome 8 (43 percent) [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Bone marrow aspiration and biopsy</span><span class="headingEndMark"> — </span>The findings on bone marrow aspiration and biopsy are similar to those seen in MM without PCL and demonstrate an increased number of monoclonal plasma cells  (<a class="graphic graphic_picture graphicRef61145" href="/z/d/graphic/61145.html" rel="external">picture 3</a>). The bone marrow infiltration is usually extensive and consists of plasma cells with a high proliferative index and anaplastic or plasmablastic morphology [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Bone marrow'</a>.)</p><p class="headingAnchor" id="H7"><span class="h2">Protein electrophoresis and immunofixation</span><span class="headingEndMark"> — </span>Protein electrophoresis of the serum and an aliquot from a 24-hour urine collection usually demonstrates monoclonal immunoglobulin production  (<a class="graphic graphic_figure graphicRef67685" href="/z/d/graphic/67685.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins", section on 'Serum protein electrophoresis (SPEP)'</a>.)</p><p>Serum immunofixation will reveal production of one of the following immunoglobulins  (<a class="graphic graphic_figure graphicRef55916" href="/z/d/graphic/55916.html" rel="external">figure 2</a>) [<a href="#rid1">1</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>IgG – 33 percent </p><p class="bulletIndent1"><span class="glyph">●</span>IgA – 20 percent </p><p class="bulletIndent1"><span class="glyph">●</span>IgD – 3 percent </p><p class="bulletIndent1"><span class="glyph">●</span>IgE – 1 percent </p><p></p><p>Approximately 35 percent of patients will have light chain only disease and less than 10 percent will be non-secretors. (See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins", section on 'Serum immunofixation'</a>.)</p><p class="headingAnchor" id="H1892070531"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H4307781"><span class="h2">Diagnostic evaluation</span><span class="headingEndMark"> — </span>The diagnosis of PCL should be suspected in patients with confirmed or suspected multiple myeloma (MM) who present with or develop any of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Circulating plasma cells on conventional leukocyte differential count/peripheral smear evaluation</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated lactate dehydrogenase (LDH)</p><p class="bulletIndent1"><span class="glyph">●</span>Hepatosplenomegaly</p><p class="bulletIndent1"><span class="glyph">●</span>Pleural effusion </p><p></p><p>Patients suspected of having PCL should be referred urgently for expert evaluation and management. Careful examination of the peripheral blood smear is key. Guidelines from the International Myeloma Working Group recommend that an experienced clinician (eg, pathologist, hematologist) systematically analyze a minimum of 100 to 200 nucleated cells per smear [<a href="#rid8">8</a>]. Flow cytometry of the peripheral blood is also performed to confirm clonality and further classify the circulating cells. Further evaluation is identical to that for suspected MM  (<a class="graphic graphic_algorithm graphicRef94388" href="/z/d/graphic/94388.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Evaluation'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>The diagnosis of PCL requires both of the following [<a href="#rid8">8</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Confirmed diagnosis of MM  (<a class="graphic graphic_table graphicRef57627" href="/z/d/graphic/57627.html" rel="external">table 1</a>).</p><p></p><p class="bulletIndent1">Bone marrow aspiration and biopsy will demonstrate a monoclonal population of plasma cells. Monoclonal protein on serum protein electrophoresis (SPEP) or urine protein electrophoresis (UPEP) supports but is not necessary for making the diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plasma cells ≥5 percent of white blood cells on conventional peripheral blood smear (manual white blood cell differential count).</p><p></p><p class="bulletIndent1">The cytoplasm of the neoplastic plasma cells must contain either kappa or lambda light chains, but not both, indicating that the cells are clonal.</p><p></p><p>Importantly, these diagnostic criteria use the plasma cells detected by manual differential count on a conventional peripheral blood smear examination and <strong>not</strong> on flow cytometry. While a 5 percent cutoff is used to define PCL, lower levels of circulating plasma cells (eg, 3 to 4 percent) on conventional peripheral smear may be associated with highly proliferative and aggressive MM [<a href="#rid16">16,17</a>]. </p><p>Almost all patients with MM have circulating plasma cells on flow cytometry due to the high sensitivity of the assay, and thus their detection cannot be used to differentiate MM from PCL [<a href="#rid18">18</a>]. In contrast, the presence of ≥5 percent plasma cells on conventional white blood cell differential count indicates a very high level of circulating plasma cells. It is this level that gives PCL a unique clinical phenotype and the need to differentiate from MM, including high-risk MM. In general, median survival of PCL is much lower than that of high-risk MM, and the classification of these patients into a unique disease entity allows for better prognostication, counseling, treatment planning, and research. (See <a class="local">'Prognosis'</a> below.)</p><p>Previously, the plasma cell cutoff used to diagnose PCL was ≥20 percent, but the International Myeloma Working Group revised the cutoff to ≥5 percent based on studies indicating that the prognosis is similar for patients meeting the lower threshold [<a href="#rid8">8,19-21</a>].</p><p>The original diagnostic criteria required both an absolute plasma cell count exceeding 2000/microL and 20 percent of the peripheral blood white cells [<a href="#rid19">19,21</a>]. However, many of the older published case series required only one of these criteria for the diagnosis. There were concerns that these stringent diagnostic criteria missed many patients with PCL. Subsequent studies have found that lower plasma cell levels (eg, 5 percent and/or absolute peripheral blood plasma cell count ≥0.5 x 10<sup>9</sup>/L) have the same prognostic impact leading to the revised disease definition for PCL [<a href="#rid2">2,8,16,17,22,23</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis of PCL includes MM as well as other leukemias and lymphomas with abnormal cells circulating in the peripheral blood. It also includes reactive polyclonal plasmacytosis that can be related to infectious or autoimmune disorders.</p><p>Most cases will be easily distinguished from other forms of leukemia and lymphoma by morphology with confirmation by flow cytometry or immunohistochemistry. </p><p>Patients with PCL are distinguished from those with MM or other plasma cell dyscrasias based on the detection of ≥5 percent plasma cells on white blood cell differential count examination in the peripheral blood. </p><p>A diagnosis of reactive polyclonal plasmacytosis can be excluded based on absence of kappa or lambda light chain restriction.</p><p class="headingAnchor" id="H10"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>The prognosis of PCL is poor, and it is worse than that of high-risk multiple myeloma (MM). While the prognosis has improved with the development of new therapies, it is difficult to accurately estimate expected survival.</p><p>Historically, the median overall survival (OS) was only 6 to 11 months, with up to 28 percent dying within the first month after diagnosis [<a href="#rid1">1,5,12,19</a>]. Survival was even shorter (two to seven months) when PCL occurred in the context of refractory or relapsed MM (ie, secondary PCL) [<a href="#rid1">1</a>]. </p><p>While still suboptimal, OS has improved modestly with the widespread use of high-dose therapy with autologous hematopoietic cell transplantation (rescue) and the availability of novel agents. This was best illustrated in an analysis of the Surveillance, Epidemiology, and End Results (SEER) database of 445 patients with primary PCL diagnosed between 1973 and 2009 that reported median OS of 5, 6, 4, and 12 months for those patients diagnosed during 1973-1995, 1996-2000, 2001-2005, and 2006-2009, respectively [<a href="#rid24">24</a>].</p><p>Prognostic models are under development. As an example, a multicenter retrospective study of 117 patients with primary PCL between 2006 and 2016 identified the following independent predictors of worse OS [<a href="#rid25">25</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Age ≥60 years </p><p class="bulletIndent1"><span class="glyph">●</span>Platelet count ≤100 x 10<sup>9</sup>/L </p><p class="bulletIndent1"><span class="glyph">●</span>Peripheral blood plasma cell count ≥20 x 10<sup>9</sup>/L </p><p></p><p>The median OS in patients with 0, 1, or 2 to 3 of these risk factors was 46, 27, and 12 months, respectively.</p><p>It is likely that the poor outcome in PCL is related to a high proliferative rate and the frequent presence of cytogenetic abnormalities known to be associated with rapidly progressive, or high risk, MM. In one retrospective study, patients with PCL were noted to have the following high-risk abnormalities [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>del13 – 67 to 85 percent</p><p class="bulletIndent1"><span class="glyph">●</span>t(4;14) – 16 percent</p><p class="bulletIndent1"><span class="glyph">●</span>t(14;16) – 16 percent</p><p class="bulletIndent1"><span class="glyph">●</span>del17p13 – 50 to 75 percent</p><p></p><p>More research is needed to better understand the impact of specific genetic findings on the prognosis of primary PCL and secondary PCL. As an example, primary PCL with t(11;14) may have better prognosis than primary PCL without t(11;14). In a study of 128 patients with primary PCL diagnosed between 2014 and 2020, the 62 cases with t(11;14) had fewer adverse cytogenetic abnormalities, a different gene expression profile, and longer median OS (39 versus 18 months) when compared with those without t(11;14) [<a href="#rid26">26</a>].</p><p>Genetic markers of high-risk MM are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/6660.html" rel="external">"Multiple myeloma: Pathobiology", section on 'Cytogenetic abnormalities'</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H16112331"><span class="h2">Pretreatment evaluation</span><span class="headingEndMark"> — </span>Because of the rigorous nature of the chemotherapy required for the treatment of PCL, particular attention should be paid in the history and physical examination to the presence of comorbid conditions in the patient that could complicate overall management. The history should pay specific attention to complaints of bone pain, constitutional symptoms, neurologic symptoms, and infections. The physical examination should include a detailed neurologic exam.</p><p>Our pretreatment evaluation also includes the following studies, some of which are performed as part of the diagnostic evaluation: </p><p class="bulletIndent1"><span class="glyph">●</span>A complete blood count and differential with examination of the peripheral blood smear. Flow cytometry of the peripheral blood.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A chemistry screen that includes measurements of serum calcium, creatinine, albumin, lactate dehydrogenase, uric acid, phosphorus, and beta-2 microglobulin. (See  <a class="medical medical_review" href="/z/d/html/6658.html" rel="external">"Multiple myeloma: Staging and prognostic studies"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serum free monoclonal light chain (FLC) measurement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A serum protein electrophoresis (SPEP) with immunofixation and quantitation of immunoglobulins. A routine urinalysis and a 24-hour urine collection for electrophoresis (UPEP) and immunofixation. (See  <a class="medical medical_review" href="/z/d/html/6655.html" rel="external">"Laboratory methods for analyzing monoclonal proteins"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow aspiration and biopsy with immunophenotyping and fluorescence in situ hybridization (FISH). FISH should include probes that identify t(11;14), t(4;14), t(6;14), t(14;16), t(14;20), del17p13, gain 1q, and trisomies of odd numbered chromosomes. FISH for del1p32 can provide additional prognostic information, if available. (See  <a class="medical medical_review" href="/z/d/html/6658.html" rel="external">"Multiple myeloma: Staging and prognostic studies", section on 'Other cytogenetic lesions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cross sectional imaging (eg, computed tomography [CT], positron emission tomography with computed tomography [PET/CT], or magnetic resonance imaging [MRI]) for the detection of bone involvement. The choice of imaging modality is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6649.html" rel="external">"Multiple myeloma: Clinical features, laboratory manifestations, and diagnosis", section on 'Choice of modality'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A study of cardiac ejection fraction (eg, echocardiogram or MUGA) should be performed prior to treatment with potentially cardiotoxic agents (eg, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>).</p><p></p><p class="headingAnchor" id="H356400128"><span class="h2">Prevention and management of complications</span><span class="headingEndMark"> — </span>In addition to therapy directed at the malignant clone, the management of PCL includes careful monitoring for and management of tumor lysis syndrome and hypercalcemia. Preventative measures to reduce the incidence of skeletal events, kidney damage, infections, neuropathy, and thrombosis are required for all patients with multiple myeloma (MM), as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6643.html" rel="external">"Multiple myeloma: Overview of management", section on 'Prevention and management of complications'</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tumor lysis syndrome</strong> – Given the high tumor burden and aggressiveness of the disease, patients with PCL are at risk for developing tumor lysis syndrome. This syndrome is best prevented via appropriate treatment with aggressive intravenous fluid hydration, prophylactic <a class="drug drug_general" data-topicid="10189" href="/z/d/drug information/10189.html" rel="external">rasburicase</a> or <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">allopurinol</a>, correction of any prior electrolyte disturbances and elements of reversible kidney failure, as well as the provision of sufficient fluids to insure a high urine output. Patients should be monitored with serum uric acid, calcium, phosphorus, and serum creatinine  (<a class="graphic graphic_algorithm graphicRef63724" href="/z/d/graphic/63724.html" rel="external">algorithm 2</a>). This is most appropriately performed in a continuously monitored inpatient setting. (See  <a class="medical medical_review" href="/z/d/html/17050.html" rel="external">"Tumor lysis syndrome: Prevention and treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypercalcemia</strong> – Patients with hypercalcemia may be asymptomatic or present with anorexia, nausea, vomiting, polyuria, polydipsia, constipation, weakness, confusion, or stupor. The treatment of hypercalcemia depends on the calcium level, the rapidity with which it developed, and the patient's symptoms. Emergency treatment with hydration, glucocorticoids, bisphosphonates, and/or hemodialysis/<a class="drug drug_general" data-topicid="9182" href="/z/d/drug information/9182.html" rel="external">calcitonin</a> is indicated for symptomatic patients. (See  <a class="medical medical_review" href="/z/d/html/850.html" rel="external">"Treatment of hypercalcemia"</a>.)</p><p></p><p class="headingAnchor" id="H16112867"><span class="h2">Initial treatment</span></p><p class="headingAnchor" id="H4075211358"><span class="h3">Goals of care and overall strategy</span><span class="headingEndMark"> — </span>Patients with PCL are not cured with conventional therapy. Treatment alleviates symptoms, reverses cytopenias, and decreases end-organ damage, and is given with the overall goals of achieving and maintaining a response, improving quality of life, and prolonging overall survival (OS).</p><p>There is no standard of care and the approach used by experts varies. When available, we encourage patients to enroll on clinical trials. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=6646" target="_blank">www.clinicaltrials.gov</a>). </p><p>Our approach is generally consistent with that of the European Myeloma Network [<a href="#rid27">27</a>]. Treatment begins as soon as possible after the diagnosis is confirmed and choice of therapy depends on eligibility for autologous hematopoietic cell transplantation (HCT) (see  <a class="medical medical_review" href="/z/d/html/16354.html" rel="external">"Determining eligibility for autologous hematopoietic cell transplantation"</a>): </p><p class="bulletIndent1"><span class="glyph">●</span>Eligible for HCT – For most patients eligible for HCT, we suggest three to six cycles of induction therapy, followed by autologous HCT and maintenance until progression or unacceptable toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ineligible for HCT – Those ineligible for HCT are treated with 8 to 12 cycles of induction therapy, followed by maintenance until progression or unacceptable toxicity.</p><p></p><p>There have been no prospective randomized trials investigating the treatment of PCL, and the vast majority of MM trials have excluded patients with active PCL. Recommendations are primarily based on data from small uncontrolled prospective studies, retrospective series, case reports, and extrapolation of data from patients with MM.</p><p class="headingAnchor" id="H12"><span class="h3">Induction therapy</span><span class="headingEndMark"> — </span>The best induction regimen for PCL is not known and there is great variability in clinical practice. Most experts offer regimens that incorporate the proteasome inhibitor <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> [<a href="#rid27">27</a>]. While initial data regarding other proteasome inhibitors (eg, <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a>) are promising, we do not use them off-label for the initial treatment of PCL.</p><p>For patients with PCL, we suggest induction therapy with one of the following bortezomib-based regimens [<a href="#rid28">28,29</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>VDT-PACE (<a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>). (See  <a class="medical medical_review" href="/z/d/html/131449.html" rel="external">"Multiple myeloma: Treatment of third or later relapse", section on 'VDT-PACE'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dara-VRd (<a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>, <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>). (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'Daratumumab, bortezomib, lenalidomide, dexamethasone'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VCd (<a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, also known as CyBorD)  (<a class="graphic graphic_table graphicRef50061" href="/z/d/graphic/50061.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VTd (<a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>)  (<a class="graphic graphic_table graphicRef101205" href="/z/d/graphic/101205.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>VRd (<a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>)  (<a class="graphic graphic_table graphicRef91054" href="/z/d/graphic/91054.html" rel="external">table 4</a>).</p><p></p><p>A choice among these depends on the patient's general health, comorbidities, and presentation. Of these, VDT-PACE is the most aggressive regimen; it may be preferred in younger, fit patients who require a rapid response. Options for patients with acute kidney failure due to cast nephropathy include VDT-PACE, VCd, and VTd; <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> is typically avoided in this population. Escalation of care to a four-drug regimen that incorporates an anti-CD38 monoclonal antibody (eg, daratumumab-VTd or daratumumab-VRd) is a reasonable option for selected patients with a suboptimal response after the first cycle. </p><p>As described in more detail below, one nonrandomized trial and several retrospective series suggest bortezomib-based combinations are active in PCL. Additional support comes from extrapolation of data from prospective trials in MM that suggest proteasome inhibitors, such as <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a>, are one of our most active therapies in patients with high-risk MM as defined by genetic abnormalities. Since patients with PCL often demonstrate these same genetic abnormalities, bortezomib has been tested in PCL, and it appears to be active. Responses have also been seen in patients treated with lenalidomide-based regimens [<a href="#rid30">30-33</a>]. In contrast, patients with PCL have had poor OS with older treatments for MM [<a href="#rid1">1,9,15</a>].</p><p>The following is a survey of studies that have investigated <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> in the treatment of PCL:</p><p class="bulletIndent1"><span class="glyph">●</span>In a phase II trial, 40 patients with PCL underwent induction with four cycles of bortezomib-based chemotherapy [<a href="#rid34">34</a>]. <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">Bortezomib</a>, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, and <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> (PAD) was given for cycles 1 and 3, and VCD was given for cycles 2 and 4. Responding patients underwent high-dose <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">melphalan</a> plus autologous HCT followed by either a second autologous HCT and maintenance therapy or a reduced-intensity allogeneic HCT. The overall response rate was 69 percent (10 percent complete). Median progression-free survival (PFS) and OS were 15 and 36 months, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A multicenter retrospective study of 73 patients with PCL included 14 patients initially treated with a regimen that contained <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> [<a href="#rid7">7</a>]. Of these, 10 (71 percent) demonstrated an at least partial response (four complete responses). Among patients initially treated with bortezomib, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, or a combination of the two drugs, the median survival was 12.6 months, but among patients responding to bortezomib, approximately half were alive without relapse at 26 months from diagnosis. In this study, the choice of initial therapy did not affect survival, but the sample size does not permit adequate comparisons, and no conclusions can be made.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another multicenter retrospective study of 42 patients with primary or secondary PCL, bortezomib-based therapy was associated with higher response rates (69 versus 31 percent) and longer median survival (13 versus 2 months) [<a href="#rid35">35</a>]. When treated with a bortezomib-based therapy, the median survival times of patients with primary and secondary PCL were 18 and 7 months, respectively.</p><p></p><p>The above reports and smaller case reports show the safety and feasibility of bortezomib-based initial therapy [<a href="#rid33">33,36-45</a>]. </p><p><a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">Carfilzomib</a> has not been directly compared with <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> in this setting. A nonrandomized, phase 2 multicenter trial (EMN 12/HOVON129) evaluated carfilzomib plus <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> as induction in primary PCL followed by tandem autologous HCT (if eligible) and consolidation and maintenance with carfilzomib and lenalidomide [<a href="#rid46">46</a>]. The transplant-ineligible population will receive the same approach but without autologous HCT. Those eligible for allogeneic HCT could receive autologous HCT followed by reduced-intensity allogeneic HCT instead of the tandem autologous HCT. Results included:</p><p class="bulletIndent1"><span class="glyph">●</span>Among the 36 patients ≤65 years, most patients had a measurable response (86 percent partial response or better, 50 percent complete response, 28 percent minimal residual disease negative). After a median follow-up of 44 months, the median PFS was 15.5 months, and the median OS was 28.4 months. There were 20 deaths: 19 from progressive disease and 1 from infection after allogeneic HCT. Early mortality was uncommon (8.3 percent at six months).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among the 25 patients ≥66 years, most patients had a measurable response (80 percent partial response or better, 36 percent complete response). After a median follow-up of 32 months, the median PFS was 13.8 months, and the median OS was 24.8 months. There were 18 deaths: 12 from disease progression, 3 from infection, 2 from other causes, and 1 unknown cause. </p><p></p><p>These results suggest that <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a> is also effective, although with moderate toxicity, especially among the older group.</p><p class="headingAnchor" id="H16113162"><span class="h3">Transplantation</span><span class="headingEndMark"> — </span>High-dose chemotherapy followed by autologous HCT improves OS in patients with MM and has become part of the standard of care for eligible patients. For HCT-eligible patients with PCL, we suggest induction therapy followed by immediate autologous HCT rather than delaying HCT until the time of relapse. A minority of patients will be eligible for allogeneic HCT. As the role of allogeneic HCT remains investigational, such transplants should ideally be conducted in the context of a clinical trial.</p><p>Prospective randomized trials of autologous or allogeneic HCT versus nontransplant strategies have not included patients with PCL. Case reports and case series have recorded some long-term responses to autologous or allogeneic HCT in PCL [<a href="#rid7">7,34,47-50</a>]. However, most of these data are based on patients who were treated with non-bortezomib-based induction regimens.</p><p>Due to the poor prognosis with chemotherapy alone in these patients, we offer high-dose chemotherapy followed by autologous stem cell rescue to eligible patients with PCL. This approach follows bortezomib-based induction therapy as discussed above. Following HCT, consideration should be given to some form of maintenance therapy to prevent relapse. </p><p>At present, the data suggest that HCT may be of value in PCL, although no definite conclusions can be made due to lack of randomized data. Further, there are no data on whether allogeneic approaches offer any additional benefit compared with autologous HCT. The following is a compilation of reports on the use of HCT in PCL along with corresponding key conclusions:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Superior outcomes with HCT when compared with nontransplant strategies</strong> – A multicenter retrospective analysis of 73 patients with primary PCL included 23 patients who had undergone a single autologous HCT (nine patients), a double autologous HCT (eight patients), an allogeneic HCT (two patients), or a tandem autologous/allogeneic HCT (four patients) [<a href="#rid7">7</a>]. Among patients who underwent HCT, the median OS and duration of response were 38 and 27 months, respectively. In this highly selected group, patients who survived initial therapy and received HCT had superior survival and response durations when compared with those who did not receive HCT.</p><p></p><p class="bulletIndent1">In another multicenter retrospective study that included 117 patients with primary PCL, 98 patients were treated with novel agents, with an overall response rate of 78 percent [<a href="#rid25">25</a>]. Of these, 55 patients (64 percent) underwent upfront autologous HCT. After a median follow-up of 50 months (95% CI 33-76), median OS for the group as a whole was 23 months (95% CI 15-34). Those who underwent upfront autologous HCT had longer median OS than those who did not receive autologous HCT (35 months [95% CI 24.3-46] versus 13 months [95% CI 6.3-35.8]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inferior outcomes following HCT for PCL when compared with MM</strong> – The largest retrospective study was conducted by the European Group for Blood and Marrow Transplantation and included 272 patients with primary PCL and 20,844 patients with MM who had undergone autologous HCT from 1980 to 2006 [<a href="#rid51">51</a>]. While patients with PCL were more likely to enter complete remission after transplantation, their median PFS (14 versus 27 months) and OS (26 versus 62 months) were inferior to that of patients with MM.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inferior outcomes following allogeneic HCT when compared with autologous HCT</strong> – A retrospective study from the Center for International Blood and Marrow Transplant Research analyzed the outcomes of patients with PCL who underwent autologous (97 patients, median age 56 years) or allogeneic (50 patients, median age 48 years) HCT within 18 months of diagnosis between 1995 and 2006 reported inferior outcomes with allogeneic compared with autologous transplantation in this patient population [<a href="#rid49">49</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Following autologous HCT – estimated three-year PFS (34 percent), relapse (61 percent), non-relapse mortality (5 percent), and OS (64 percent)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Following allogeneic HCT – estimated three-year PFS (20 percent), relapse (38 percent), non-relapse mortality (41 percent), and OS (39 percent)</p><p></p><p class="bulletIndent1">In a phase II trial of 40 patients with PCL treated with bortezomib-based induction, responding patients underwent autologous HCT followed by either a second autologous HCT (6 patients) or reduced-intensity allogeneic HCT (16 patients) [<a href="#rid34">34</a>]. For the entire cohort, median PFS and OS were 15 and 36 months, respectively. The median OS was not reached for those undergoing autologous HCT and was 36 months for those undergoing allogeneic HCT. Part of this survival benefit may reflect selection bias with younger patients who survived initial therapy proceeding to HCT.</p><p></p><p class="headingAnchor" id="H16113105"><span class="h3">Maintenance</span><span class="headingEndMark"> — </span>For all patients with PCL, we suggest maintenance with <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and/or <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> rather than observation until relapse. Two-drug maintenance is preferable, if tolerated. This preference is based on the short remission durations (14 months) seen in these patients and the relatively mild toxicity of maintenance. Ongoing clinical trials (eg, EMN12/HOVON 129) are evaluating maintenance with lenalidomide plus <a class="drug drug_general" data-topicid="86042" href="/z/d/drug information/86042.html" rel="external">carfilzomib</a>, and we consider this combination investigational. </p><p>There have been no randomized studies of maintenance therapy in patients with PCL. However, since virtually all patients with PCL who attain a complete remission develop relapsed disease, consideration should be given to some form of maintenance therapy. </p><p>Maintenance can prolong PFS in patients with MM. The benefits of improved PFS must be balanced against an increased rate of severe (grade 3/4) neutropenia, risk of second cancers and other toxicities, the cost, and the possibility that the PFS advantage may be neutralized by the use of <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> at time of first relapse.</p><p>Studies evaluating the use of maintenance therapy in patients with MM are presented separately. (See  <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">"Multiple myeloma: Initial treatment", section on 'Maintenance for patients who are ineligible for or defer HCT'</a> and  <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'High-risk disease'</a>.)</p><p class="headingAnchor" id="H16113495"><span class="h2">Response assessment</span><span class="headingEndMark"> — </span>Patients should be evaluated before each treatment cycle to determine how their disease is responding to therapy. Response is evaluated using specific criteria from the International Myeloma Working Group that incorporate response features used for acute leukemia and for MM  (<a class="graphic graphic_table graphicRef89246" href="/z/d/graphic/89246.html" rel="external">table 5</a>) [<a href="#rid2">2</a>]. </p><p>This assessment includes the following: </p><p class="bulletIndent1"><span class="glyph">●</span>Quantitation of peripheral blood plasma cells by morphologic review of the peripheral smear</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Measurement of monoclonal (M) protein in the serum and urine (SPEP, UPEP)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evaluation of previously identified or suspected extramedullary disease</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone marrow evaluation is incorporated to identify complete response or better</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The FLC assay and flow cytometry or immunohistochemistry of the bone marrow are incorporated to identify stringent complete remission</p><p></p><p>The goal of therapy in PCL is to achieve and maintain a complete response, as much as possible; this goal therefore influences the choice of the initial treatment options. However, since the disease is not considered curable, failure to achieve a complete response should not be construed as a reason to change or intensify therapy. There are no data that such an approach leads to superior survival. In selected patients with good performance status who respond but fail to achieve complete response, after a full discussion of the pros and cons, consideration can be given to allogeneic HCT and other options used for patients with relapsed/refractory disease. (See  <a class="medical medical_review" href="/z/d/html/6656.html" rel="external">"Multiple myeloma: Use of hematopoietic cell transplantation", section on 'Allogeneic HCT'</a>.)</p><p>Relapse from complete remission is identified by the reappearance of a monoclonal protein, the development of extramedullary disease, reappearance of circulating plasma cells, or an increase in the bone marrow plasma cells to &gt;10 percent [<a href="#rid2">2</a>]. Therapy should be reinstated at the time of relapse.</p><p class="headingAnchor" id="H16113536"><span class="h2">Treatment of recurrent or refractory disease</span><span class="headingEndMark"> — </span>There is limited information to guide the treatment of recurrent or refractory PCL and care is individualized. </p><p>Options include a trial of another regimen active in MM; retreatment with previously effective regimens (if the relapse occurred off-therapy); and transplantation. Options for relapsed or refractory MM are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">"Multiple myeloma: Treatment of first or second relapse"</a> and  <a class="medical medical_review" href="/z/d/html/131449.html" rel="external">"Multiple myeloma: Treatment of third or later relapse"</a>.)</p><p>The following treatments are of particular interest in relapsed PCL:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Daratumumab</strong><strong>-based regimens</strong> – As PCL expresses CD38, regimens that include an anti-CD38 monoclonal antibody (eg, <a class="drug drug_general" data-topicid="105443" href="/z/d/drug information/105443.html" rel="external">daratumumab</a>, <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a>, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>  (<a class="graphic graphic_table graphicRef119710" href="/z/d/graphic/119710.html" rel="external">table 6</a>)) are an attractive option and initial reports suggest that they are active. Efficacy data are primarily from case reports. A retrospective study reported outcomes in 28 patients with PCL treated with daratumumab-based combinations [<a href="#rid52">52</a>]. Among the 14 patients with primary PCL (four previously untreated), 11 patients (79 percent) achieved an at least partial response and the median PFS was 20 months. Among the 14 patients with secondary PCL, 8 patients (57 percent) achieved a partial response or better and the median PFS was 5 months. Daratumumab-containing regimens used for MM are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/121127.html" rel="external">"Multiple myeloma: Treatment of first or second relapse"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Venetoclax</strong><strong> for t(11;14)-positive disease</strong> – There is also interest in <a class="drug drug_general" data-topicid="107696" href="/z/d/drug information/107696.html" rel="external">venetoclax</a> because the t(11;14) has been reported in 45 to 70 percent of patients with PCL. Several cases reports have described responses to venetoclax or venetoclax-containing therapy [<a href="#rid53">53-59</a>]. Further data are needed to better understand the efficacy and toxicity of this agent in PCL. Use in MM is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/131449.html" rel="external">"Multiple myeloma: Treatment of third or later relapse", section on 'Venetoclax for MM with t(11;14)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transplantation and other cellular therapies</strong> – Patients who are eligible may be considered for allogeneic HCT, or an autologous HCT followed by an allogeneic HCT. Patients who have undergone allogeneic HCT may respond to withdrawal of immunosuppression or immunotherapy with donor lymphocyte infusion. (See <a class="local">'Transplantation'</a> above.) </p><p></p><p class="bulletIndent1">Data regarding BCMA-directed chimeric antigen receptor (CAR)-T cell therapies are limited. PCL was an exclusion criterion in the trials conducted for the approval of <a class="drug drug_general" data-topicid="131213" href="/z/d/drug information/131213.html" rel="external">idecabtagene vicleucel</a> and <a class="drug drug_general" data-topicid="135088" href="/z/d/drug information/135088.html" rel="external">ciltacabtagene autoleucel</a>. A study conducted in China evaluated the efficacy and safety of a BCMA-CAR-T in 30 patients with relapsed/refractory MM, two of whom had primary PCL [<a href="#rid60">60</a>]. One patient achieved a complete response with a PFS of 307 days and the other patient achieved a very good partial response with a PFS of 117 days. (See  <a class="medical medical_review" href="/z/d/html/131449.html" rel="external">"Multiple myeloma: Treatment of third or later relapse", section on 'Chimeric antigen receptor T cells'</a>.)</p><p></p><p>Often there is no better therapy to offer a patient than enrollment onto a well-designed, scientifically valid, peer-reviewed clinical trial. Additional information and instructions for referring a patient to an appropriate research center can be obtained from the United States National Institutes of Health (<a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=6646" target="_blank">www.clinicaltrials.gov</a>).</p><p class="headingAnchor" id="H1292087127"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114824.html" rel="external">"Society guideline links: Multiple myeloma"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Plasma cell leukemia (PCL) is a rare, yet aggressive variant of multiple myeloma (MM) characterized by plasma cells circulating in the peripheral blood. PCL can either originate de novo (primary PCL) or as a secondary leukemic transformation of MM (secondary PCL). </p><p></p><p class="bulletIndent1">Presenting signs and symptoms can include those seen in MM (eg, kidney dysfunction, hypercalcemia, lytic bone lesions, anemia) and in other leukemias (eg, anemia, thrombocytopenia, infections, hepatomegaly, splenomegaly). (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnostic evaluation</strong> – The diagnosis of PCL should be suspected in patients with confirmed or suspected MM who present with or develop any of the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Circulating plasma cells on conventional leukocyte differential count/peripheral smear evaluation</p><p class="bulletIndent2"><span class="glyph">•</span>Elevated lactate dehydrogenase (LDH)</p><p class="bulletIndent2"><span class="glyph">•</span>Hepatosplenomegaly</p><p class="bulletIndent2"><span class="glyph">•</span>Pleural effusion </p><p></p><p class="bulletIndent1">Patients suspected of having PCL should be referred urgently for expert evaluation, which includes careful examination of the peripheral blood smear, flow cytometry of the peripheral blood, and evaluation for suspected MM  (<a class="graphic graphic_algorithm graphicRef94388" href="/z/d/graphic/94388.html" rel="external">algorithm 1</a>). (See <a class="local">'Pathologic features'</a> above.)</p><p></p><p class="bulletIndent1">Diagnosis of PCL requires both a confirmed diagnosis of MM  (<a class="graphic graphic_table graphicRef57627" href="/z/d/graphic/57627.html" rel="external">table 1</a>) and ≥5 percent plasma cells on white blood cell differential count on conventional peripheral blood smear evaluation. (See <a class="local">'Diagnostic criteria'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial treatment</strong> – While not curative, treatment aims to improve quality of life and extend survival. There is no standard of care and the approach used by experts varies. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1">Treatment begins as soon as possible after diagnosis, and choice of therapy depends on eligibility for autologous hematopoietic cell transplantation (HCT):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Eligible for HCT – For most patients eligible for HCT, we administer three to six cycles of induction therapy, followed by autologous HCT and maintenance until progression or unacceptable toxicity.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ineligible for HCT – Those ineligible for HCT are treated with 8 to 12 cycles of induction therapy, followed by maintenance until progression or unacceptable toxicity.</p><p></p><p class="bulletIndent1">For most patients with PCL we suggest a multidrug induction regimen that includes <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For young, fit patients, we suggest VDT-PACE (bortezomib, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">etoposide</a>) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Alternatives for less-fit patients are discussed above. (See <a class="local">'Induction therapy'</a> above.)</p><p></p><p class="bulletIndent1">For patients who are candidates for transplantation, we suggest proceeding after induction therapy to high-dose therapy plus autologous HCT rather than delaying HCT until the time of relapse (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Transplantation'</a> above.)</p><p></p><p class="bulletIndent1">For most patients, we suggest maintenance with <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> and <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> rather than single-drug maintenance or observation until relapse (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, if not tolerated, single-drug maintenance is an acceptable alternative. (See <a class="local">'Maintenance'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsed or refractory disease</strong> – There is limited information to guide the treatment of recurrent or refractory PCL and care is individualized. Options include a trial of another regimen active in MM; retreatment with previously effective regimens (if the relapse occurred off-therapy); and transplantation. (See <a class="local">'Treatment of recurrent or refractory disease'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008; 22:1044.</a></li><li><a class="nounderline abstract_t">Fernández de Larrea C, Kyle RA, Durie BG, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia 2013; 27:780.</a></li><li><a class="nounderline abstract_t">Bladé J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am 1999; 13:1259.</a></li><li><a class="nounderline abstract_t">Gertz MA. Managing plasma cell leukemia. Leuk Lymphoma 2007; 48:5.</a></li><li><a class="nounderline abstract_t">Ramsingh G, Mehan P, Luo J, et al. Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer 2009; 115:5734.</a></li><li><a class="nounderline abstract_t">Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116:3724.</a></li><li><a class="nounderline abstract_t">Pagano L, Valentini CG, De Stefano V, et al. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol 2011; 22:1628.</a></li><li><a class="nounderline abstract_t">Fernández de Larrea C, Kyle R, Rosiñol L, et al. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage. Blood Cancer J 2021; 11:192.</a></li><li><a class="nounderline abstract_t">García-Sanz R, Orfão A, González M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999; 93:1032.</a></li><li><a class="nounderline abstract_t">Kraj M, Pogłód R, Kopeć-Szlezak J, et al. C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies. Leuk Lymphoma 2004; 45:2281.</a></li><li><a class="nounderline abstract_t">Kraj M, Kopeć-Szlęzak J, Pogłód R, Kruk B. Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia. Leuk Res 2011; 35:169.</a></li><li><a class="nounderline abstract_t">Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématologique. Blood 2001; 97:822.</a></li><li><a class="nounderline abstract_t">Papadhimitriou SI, Terpos E, Liapis K, et al. The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells. Biomedicines 2022; 10.</a></li><li><a class="nounderline abstract_t">Gutiérrez NC, Hernández JM, García JL, et al. Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia 2001; 15:840.</a></li><li><a class="nounderline abstract_t">Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R. Primary plasma cell leukaemia. Br J Haematol 1994; 88:754.</a></li><li><a class="nounderline abstract_t">Ravi P, Kumar SK, Roeker L, et al. Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma. Blood Cancer J 2018; 8:116.</a></li><li><a class="nounderline abstract_t">An G, Qin X, Acharya C, et al. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients. Ann Hematol 2015; 94:257.</a></li><li><a class="nounderline abstract_t">Sanoja-Flores L, Flores-Montero J, Garcés JJ, et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J 2018; 8:117.</a></li><li><a class="nounderline abstract_t">Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med 1987; 83:1062.</a></li><li class="breakAll">Grogan TM, Van Camp B, Kyle RA. Plasma cell neoplasms. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2001. p.142.</li><li><a class="nounderline abstract_t">Kyle RA, Maldonado JE, Bayrd ED. Plasma cell leukemia. Report on 17 cases. Arch Intern Med 1974; 133:813.</a></li><li><a class="nounderline abstract_t">Evans LA, Jevremovic D, Nandakumar B, et al. Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia. Am J Hematol 2020; 95:637.</a></li><li><a class="nounderline abstract_t">Granell M, Calvo X, Garcia-Guiñón A, et al. Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. Haematologica 2017; 102:1099.</a></li><li><a class="nounderline abstract_t">Gonsalves WI, Rajkumar SV, Go RS, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood 2014; 124:907.</a></li><li><a class="nounderline abstract_t">Jurczyszyn A, Radocha J, Davila J, et al. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. Br J Haematol 2018; 180:831.</a></li><li><a class="nounderline abstract_t">Cazaubiel T, Leleu X, Perrot A, et al. Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features. Blood 2022; 139:2666.</a></li><li><a class="nounderline abstract_t">Gavriatopoulou M, Musto P, Caers J, et al. European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. Leukemia 2018; 32:1883.</a></li><li><a class="nounderline abstract_t">Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 2008; 140:625.</a></li><li><a class="nounderline abstract_t">Santamaría CM, Chillón MC, García-Sanz R, et al. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. Blood 2009; 114:148.</a></li><li><a class="nounderline abstract_t">Musto P, Pietrantuono G, Guariglia R, et al. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res 2008; 32:1637.</a></li><li><a class="nounderline abstract_t">Benson DM Jr, Smith MK. Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia. Leuk Lymphoma 2007; 48:1423.</a></li><li><a class="nounderline abstract_t">Musto P, Simeon V, Martorelli MC, et al. Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. Leukemia 2014; 28:222.</a></li><li><a class="nounderline abstract_t">Mina R, Joseph NS, Kaufman JL, et al. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer 2019; 125:416.</a></li><li><a class="nounderline abstract_t">Royer B, Minvielle S, Diouf M, et al. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome. J Clin Oncol 2016; 34:2125.</a></li><li><a class="nounderline abstract_t">Katodritou E, Terpos E, Kelaidi C, et al. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group. Am J Hematol 2014; 89:145.</a></li><li><a class="nounderline abstract_t">Esparís-Ogando A, Alegre A, Aguado B, et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005; 114:665.</a></li><li><a class="nounderline abstract_t">Jaskiewicz AD, Herrington JD, Wong L. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy 2005; 25:1820.</a></li><li><a class="nounderline abstract_t">Grassinger J, Südhoff T, Andreesen R, Hennemann B. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann Hematol 2006; 85:132.</a></li><li><a class="nounderline abstract_t">Ataergin S, Arpaci F, Kaya A, et al. VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia. Am J Hematol 2006; 81:987.</a></li><li><a class="nounderline abstract_t">Finnegan DP, Kettle P, Drake M, et al. Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma 2006; 47:1670.</a></li><li><a class="nounderline abstract_t">Ali R, Beksac M, Ozkalemkas F, et al. Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia. Leuk Lymphoma 2007; 48:1426.</a></li><li><a class="nounderline abstract_t">Katodritou E, Verrou E, Gastari V, et al. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Leuk Res 2008; 32:1153.</a></li><li><a class="nounderline abstract_t">Musto P, Rossini F, Gay F, et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 2007; 109:2285.</a></li><li><a class="nounderline abstract_t">Gozzetti A, Musto P, Defina M, et al. Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia. Br J Haematol 2012; 157:497.</a></li><li><a class="nounderline abstract_t">D'Arena G, Valentini CG, Pietrantuono G, et al. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol 2012; 23:1499.</a></li><li><a class="nounderline abstract_t">van de Donk NWCJ, Minnema MC, van der Holt B, et al. Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study. Lancet Oncol 2023; 24:1119.</a></li><li><a class="nounderline abstract_t">Saccaro S, Fonseca R, Veillon DM, et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol 2005; 78:288.</a></li><li><a class="nounderline abstract_t">Hovenga S, de Wolf JT, Klip H, Vellenga E. Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature. Bone Marrow Transplant 1997; 20:901.</a></li><li><a class="nounderline abstract_t">Mahindra A, Kalaycio ME, Vela-Ojeda J, et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia 2012; 26:1091.</a></li><li><a class="nounderline abstract_t">Nishihori T, Abu Kar SM, Baz R, et al. Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013; 19:1144.</a></li><li><a class="nounderline abstract_t">Drake MB, Iacobelli S, van Biezen A, et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica 2010; 95:804.</a></li><li><a class="nounderline abstract_t">Parrondo RD, Moustafa MA, Reeder C, et al. Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia. Clin Lymphoma Myeloma Leuk 2021; 21:355.</a></li><li><a class="nounderline abstract_t">Vo K, Guan T, Banerjee R, et al. Complete response following treatment of plasma cell leukemia with venetoclax and dexamethasone: A case report. J Oncol Pharm Pract 2022; 28:1244.</a></li><li><a class="nounderline abstract_t">Roy T, An JB, Doucette K, et al. Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression. Leuk Lymphoma 2022; 63:759.</a></li><li><a class="nounderline abstract_t">Valliani S, Ali M, Mahmoo O, et al. Efficacy of Venetoclax and Dexamethasone in Refractory IgM Primary Plasma Cell Leukemia with t(11;14) and TP53 Mutation: A Case Report and Literature Review. Case Rep Hematol 2020; 2020:8823877.</a></li><li><a class="nounderline abstract_t">Kupsh A, Arnall J, Voorhees P. A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia. J Oncol Pharm Pract 2020; 26:1274.</a></li><li><a class="nounderline abstract_t">Nalghranyan S, Singh AP, Schinke C. The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia. Am J Hematol 2020; 95:E34.</a></li><li><a class="nounderline abstract_t">Jelinek T, Mihalyova J, Kascak M, et al. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14). Am J Hematol 2019; 94:E35.</a></li><li><a class="nounderline abstract_t">Gonsalves WI, Buadi FK, Kumar SK. Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). Eur J Haematol 2018; 100:215.</a></li><li><a class="nounderline abstract_t">Li C, Cao W, Que Y, et al. A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia. Clin Transl Med 2021; 11:e346.</a></li></ol></div><div id="topicVersionRevision">Topic 6646 Version 47.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18216867" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Genetic aberrations and survival in plasma cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23288300" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10626149" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17325841" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Managing plasma cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19877113" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20664057" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21252060" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Primary plasma cell leukemia: a retrospective multicenter study of 73 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34857730" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9920853" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15512818" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20553988" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Flow cytometric immunophenotypic characteristics of 36 cases of plasma cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11157506" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du Myélome and the Groupe Français de Cytogénétique Hématologique.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35203419" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The Cytogenetic Profile of Primary and Secondary Plasma Cell Leukemia: Etiopathogenetic Perspectives, Prognostic Impact and Clinical Relevance to Newly Diagnosed Multiple Myeloma with Differential Circulating Clonal Plasma Cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11368447" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7819100" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Primary plasma cell leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30442928" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Revised diagnostic criteria for plasma cell leukemia: results of a Mayo Clinic study with comparison of outcomes to multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25231928" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30455467" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3503574" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Plasma cell leukemia: an evaluation of response to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3503574" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Plasma cell leukemia: an evaluation of response to therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4821776" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Plasma cell leukemia. Report on 17 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32129510" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28255016" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24957143" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Trends in survival of patients with primary plasma cell leukemia: a population-based analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29315478" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35171994" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Primary plasma cell leukemias displaying t(11;14) have specific genomic, transcriptional, and clinical features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30038381" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18302711" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19398719" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18433866" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17613775" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23958922" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30332496" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27114594" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24123068" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15609327" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Bortezomib is an efficient agent in plasma cell leukemias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16305302" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16311736" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16888783" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16966282" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Bortezomib is effective in primary plasma cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17613776" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18083228" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17469169" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy and safety of bortezomib in patients with plasma cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22296516" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22039089" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37717583" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15795922" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9404934" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22042147" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23416092" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Therapeutic advances in the treatment of primary plasma cell leukemia: a focus on hematopoietic cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20442444" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Primary plasma cell leukemia and autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33563579" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35084252" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Complete response following treatment of plasma cell leukemia with venetoclax and dexamethasone: A case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35076333" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33425404" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Efficacy of Venetoclax and Dexamethasone in Refractory IgM Primary Plasma Cell Leukemia with t(11;14) and TP53 Mutation: A Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31865846" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31709578" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30370955" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29064593" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33784005" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
